| Title: | Large-Scale Sequencing in the UK Biobank to Facilitate Gene Discovery, Genome Sciences, and Precision Medicine |
| Lead Institution: | Regeneron Genetics Center, LLC |
| Principal investigator: | Dr Aris Baras |
Application 26041
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
About
1. The primary scientific goal of the research is to apply human genetics to the identification of new drug targets, the validation of existing targets and therapeutics, and the discovery of biomarkers that may correlate with treatment response or aid in stratifying patients and diseases at a genetic or molecular level. In addition to the direct benefit of advancing the development of new medicines and benefiting patients, this research will also accelerate our understanding of the role of genetics in human health and disease. (continued in Annex A) The research project will generate sequencing data on up to 500,000 UK Biobank participants. This will be combined with phenotypic data that is available from UK Biobank participants, with the purpose of improving our understanding of the relationship between genetic variation and human traits. Such a resource will be one of the largest of its kind and will be made available to UK Biobank. It is anticipated that this resource will greatly facilitate research into the role of genetic variation in human health and disease and has the potential to make a significant impact on health-related research (see Annex A) The scope of the research program includes, (i) transfer of de-identified phenotypic data and genotype data to joint Applicants (RGC and GSK), (ii) transfer of biospecimens from UK Biobank to the Regeneron Genetics Center (RGC), (iii) whole exome sequencing of DNA samples by the RGC, (iv) transfer of genomic sequence data to GSK and UK Biobank by RGC and (v) analyses of the datasets in accordance with the goals, aims, and study designs described in this application by each of the Applicants (RGC and GSK), either jointly or independently. Under this research project, the Applicants endeavour to sequence DNA samples from all current UK Biobank participants (the full cohort of approximately 500,000 participants). The Applicants have established various project phases, in which they aim to sequence a certain number of samples per project phase. After completion of each project phase, the Applicants will determine whether they will proceed with the subsequent project phase. The project phases and target number of participant samples to be sequenced is detailed in the applicable section below.33 Publications
Enabling scientific discoveries that improve human health